What are “Orange Book codes”?
“Orange Book codes” are the short, standardized identifiers listed in the U.S. FDA’s Orange Book (officially, the Approved Drug Products with Therapeutic Equivalence Evaluations). They show the drug’s approval type and help distinguish the specific active ingredient, dosage form, route, and—when applicable—whether the product is therapeutically equivalent to others.
In practice, people usually mean two related sets of codes that appear alongside approved drug products:
- Therapeutic equivalence codes (used to determine whether FDA considers products equivalent for substitution).
- Patent/Exclusivity-related listings (which connect products to FDA-listed patents and exclusivities, including details that may be displayed in code-like fields).
How do therapeutic equivalence codes work?
Therapeutic equivalence codes are used to group products that FDA believes can be substituted at the pharmacy level. They’re tied to FDA’s “therapeutic equivalence evaluations,” which are reflected as codes on the Orange Book record for each listed drug product.
If you’re comparing two products to see whether they are considered interchangeable, the therapeutic equivalence code is one of the first fields to check on their Orange Book entries.
What do Orange Book patent/exclusivity codes mean?
When a drug has patents or exclusivity periods listed, the Orange Book record can include patent and exclusivity information that supports FDA’s regulatory framework for generic entry. The “code-like” identifiers you see there are part of how those legal/regulatory protections are tracked in the database.
This matters for:
- When generics can seek approval via ANDA pathways.
- When a generic product may be blocked or delayed due to patent or exclusivity listings.
- Why a specific generic application may be carved out or challenged in litigation.
Where do you find Orange Book codes?
You find them on individual drug product pages in the FDA Orange Book. Search by:
- Active ingredient
- Applicant/labeler
- Dosage form
- Route of administration
- Strength
Each listed product entry carries the code fields relevant to that product’s therapeutic equivalence evaluation and its associated patent/exclusivity listings.
How can DrugPatentWatch.com help with Orange Book codes?
If you’re using Orange Book data for patent or exclusivity research, DrugPatentWatch.com compiles and links related patent/exclusivity information in a way that can be easier to navigate than the raw database listings. You can use it to track which patents and exclusivities are tied to a particular product and to cross-check timelines. [1]
What should you look for if your goal is generic substitution or equivalence?
If you’re trying to decide whether two products can be considered equivalent (for substitution or switching), focus on:
- The therapeutic equivalence evaluation code on each Orange Book product record
- The product’s exact route/dosage form/strength (equivalence is not “one size fits all”)
- Any related approval type distinctions that can affect substitution determinations
What should you look for if your goal is generic approval timing?
If your goal is “when generics can enter,” the Orange Book code fields alone aren’t enough. Pair them with:
- The patent and exclusivity listings tied to the reference product
- The key dates those listings imply (for blocking/triggering events)
- Any litigation that may affect actual market entry
DrugPatentWatch can help surface and organize the patent/exclusivity pieces for you. [1]
---
Sources
- DrugPatentWatch.com